Cisplatin and full dose irradiation for patients with invasive bladder carcinoma: A preliminary report of tolerance and local response

W. U. Shipley, L. J. Coombs, A. B. Einstein, M. S. Soloway, Z. Wajsman, G. R. Prout

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Twenty-seven patients with invasive bladder carcinoma (clinical stages T2 to T4) who were not candidates for cystectomy were treated by transurethral resection, cis-diamminedichloroplatinum (cisplatin) and full dose radiotherapy according to protocol 8 of the National Bladder Cancer Collaborative Group A. Nausea and vomiting occurred in 74 per cent of the patients but were mild in 41 per cent. Maximum followup was 27 months and during that time 3 significant toxic reactions occurred: renal failure, systemic sepsis and a transient partial small bowel obstruction. Of 17 evaluable patients complete responses of the primary bladder cancer to the treatment were achieved in 11 of 13 with stages cT2 and cT3 cancer and in 2 of 4 with stage cT4 disease. The members of National Bladder Cancer Collaborative Group A have found transurethral resection, cisplatin and full dose external beam radiotherapy practical clinically. Longer followup will be necessary to determine if the observed high initial complete response rate of the tumor indicates real lasting benefit for these patients.

Original languageEnglish
Pages (from-to)899-903
Number of pages5
JournalJournal of Urology
Volume132
Issue number5
StatePublished - Dec 19 1984
Externally publishedYes

Fingerprint

Cisplatin
Urinary Bladder
Urinary Bladder Neoplasms
Carcinoma
Radiotherapy
Poisons
Cystectomy
Nausea
Vomiting
Renal Insufficiency
Neoplasms
Sepsis
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Shipley, W. U., Coombs, L. J., Einstein, A. B., Soloway, M. S., Wajsman, Z., & Prout, G. R. (1984). Cisplatin and full dose irradiation for patients with invasive bladder carcinoma: A preliminary report of tolerance and local response. Journal of Urology, 132(5), 899-903.

Cisplatin and full dose irradiation for patients with invasive bladder carcinoma : A preliminary report of tolerance and local response. / Shipley, W. U.; Coombs, L. J.; Einstein, A. B.; Soloway, M. S.; Wajsman, Z.; Prout, G. R.

In: Journal of Urology, Vol. 132, No. 5, 19.12.1984, p. 899-903.

Research output: Contribution to journalArticle

Shipley, WU, Coombs, LJ, Einstein, AB, Soloway, MS, Wajsman, Z & Prout, GR 1984, 'Cisplatin and full dose irradiation for patients with invasive bladder carcinoma: A preliminary report of tolerance and local response', Journal of Urology, vol. 132, no. 5, pp. 899-903.
Shipley, W. U. ; Coombs, L. J. ; Einstein, A. B. ; Soloway, M. S. ; Wajsman, Z. ; Prout, G. R. / Cisplatin and full dose irradiation for patients with invasive bladder carcinoma : A preliminary report of tolerance and local response. In: Journal of Urology. 1984 ; Vol. 132, No. 5. pp. 899-903.
@article{ff1d8924175a4cc8954bd4b656964ac9,
title = "Cisplatin and full dose irradiation for patients with invasive bladder carcinoma: A preliminary report of tolerance and local response",
abstract = "Twenty-seven patients with invasive bladder carcinoma (clinical stages T2 to T4) who were not candidates for cystectomy were treated by transurethral resection, cis-diamminedichloroplatinum (cisplatin) and full dose radiotherapy according to protocol 8 of the National Bladder Cancer Collaborative Group A. Nausea and vomiting occurred in 74 per cent of the patients but were mild in 41 per cent. Maximum followup was 27 months and during that time 3 significant toxic reactions occurred: renal failure, systemic sepsis and a transient partial small bowel obstruction. Of 17 evaluable patients complete responses of the primary bladder cancer to the treatment were achieved in 11 of 13 with stages cT2 and cT3 cancer and in 2 of 4 with stage cT4 disease. The members of National Bladder Cancer Collaborative Group A have found transurethral resection, cisplatin and full dose external beam radiotherapy practical clinically. Longer followup will be necessary to determine if the observed high initial complete response rate of the tumor indicates real lasting benefit for these patients.",
author = "Shipley, {W. U.} and Coombs, {L. J.} and Einstein, {A. B.} and Soloway, {M. S.} and Z. Wajsman and Prout, {G. R.}",
year = "1984",
month = "12",
day = "19",
language = "English",
volume = "132",
pages = "899--903",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Cisplatin and full dose irradiation for patients with invasive bladder carcinoma

T2 - A preliminary report of tolerance and local response

AU - Shipley, W. U.

AU - Coombs, L. J.

AU - Einstein, A. B.

AU - Soloway, M. S.

AU - Wajsman, Z.

AU - Prout, G. R.

PY - 1984/12/19

Y1 - 1984/12/19

N2 - Twenty-seven patients with invasive bladder carcinoma (clinical stages T2 to T4) who were not candidates for cystectomy were treated by transurethral resection, cis-diamminedichloroplatinum (cisplatin) and full dose radiotherapy according to protocol 8 of the National Bladder Cancer Collaborative Group A. Nausea and vomiting occurred in 74 per cent of the patients but were mild in 41 per cent. Maximum followup was 27 months and during that time 3 significant toxic reactions occurred: renal failure, systemic sepsis and a transient partial small bowel obstruction. Of 17 evaluable patients complete responses of the primary bladder cancer to the treatment were achieved in 11 of 13 with stages cT2 and cT3 cancer and in 2 of 4 with stage cT4 disease. The members of National Bladder Cancer Collaborative Group A have found transurethral resection, cisplatin and full dose external beam radiotherapy practical clinically. Longer followup will be necessary to determine if the observed high initial complete response rate of the tumor indicates real lasting benefit for these patients.

AB - Twenty-seven patients with invasive bladder carcinoma (clinical stages T2 to T4) who were not candidates for cystectomy were treated by transurethral resection, cis-diamminedichloroplatinum (cisplatin) and full dose radiotherapy according to protocol 8 of the National Bladder Cancer Collaborative Group A. Nausea and vomiting occurred in 74 per cent of the patients but were mild in 41 per cent. Maximum followup was 27 months and during that time 3 significant toxic reactions occurred: renal failure, systemic sepsis and a transient partial small bowel obstruction. Of 17 evaluable patients complete responses of the primary bladder cancer to the treatment were achieved in 11 of 13 with stages cT2 and cT3 cancer and in 2 of 4 with stage cT4 disease. The members of National Bladder Cancer Collaborative Group A have found transurethral resection, cisplatin and full dose external beam radiotherapy practical clinically. Longer followup will be necessary to determine if the observed high initial complete response rate of the tumor indicates real lasting benefit for these patients.

UR - http://www.scopus.com/inward/record.url?scp=0021185191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021185191&partnerID=8YFLogxK

M3 - Article

C2 - 6436510

AN - SCOPUS:0021185191

VL - 132

SP - 899

EP - 903

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -